Insider Selling: SiBone (NASDAQ:SIBN) CFO Sells 5,229 Shares of Stock

by · The Cerbat Gem

SiBone (NASDAQ:SIBN – Get Free Report) CFO Anshul Maheshwari sold 5,229 shares of SiBone stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $19.64, for a total value of $102,697.56. Following the sale, the chief financial officer owned 180,002 shares of the company’s stock, valued at approximately $3,535,239.28. This represents a 2.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

  • On Thursday, December 18th, Anshul Maheshwari sold 18,542 shares of SiBone stock. The stock was sold at an average price of $20.15, for a total transaction of $373,621.30.
  • On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The shares were sold at an average price of $20.00, for a total transaction of $2,000.00.
  • On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The stock was sold at an average price of $20.01, for a total transaction of $24,012.00.
  • On Monday, November 17th, Anshul Maheshwari sold 3,460 shares of SiBone stock. The stock was sold at an average price of $17.43, for a total value of $60,307.80.
  • On Tuesday, November 11th, Anshul Maheshwari sold 2,601 shares of SiBone stock. The shares were sold at an average price of $18.33, for a total value of $47,676.33.

SiBone Stock Performance

Shares of SIBN stock traded up $0.43 during trading on Tuesday, reaching $20.40. The company had a trading volume of 412,471 shares, compared to its average volume of 464,090. The firm’s 50 day simple moving average is $18.49 and its two-hundred day simple moving average is $17.01. SiBone has a one year low of $12.49 and a one year high of $21.07. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. The company has a market capitalization of $885.18 million, a PE ratio of -40.00 and a beta of 0.69.

SiBone (NASDAQ:SIBN – Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The company had revenue of $48.66 million for the quarter, compared to the consensus estimate of $46.67 million. Sell-side analysts forecast that SiBone will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SIBN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Truist Financial lifted their price objective on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Needham & Company LLC boosted their price objective on SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Morgan Stanley raised their target price on SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Canaccord Genuity Group lifted their price target on shares of SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

Check Out Our Latest Stock Report on SiBone

Hedge Funds Weigh In On SiBone

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after acquiring an additional 1,053 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in SiBone during the 1st quarter valued at $225,000. Goldman Sachs Group Inc. raised its position in SiBone by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock valued at $5,328,000 after purchasing an additional 83,919 shares during the last quarter. Jane Street Group LLC bought a new position in SiBone in the 1st quarter valued at $1,818,000. Finally, Rhumbline Advisers boosted its stake in SiBone by 3.6% in the first quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock worth $838,000 after purchasing an additional 2,100 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

About SiBone

(Get Free Report)

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.

Read More